Caris Life Sciences, Inc. cash flow to debt ratio of 21.94% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Caris Life Sciences, Inc.'s free cash flow has increased -126.37% from $-253.64M last year to $66.89M, signaling increasing performance

Caris Life Sciences, Inc.'s debt to equity ratio is 0.76, which means that the company's assets are unhealthy financed, signaling financial risk.

Caris Life Sciences, Inc.'s debt has increased relative to shareholder equity from -0.17 last year to 0.76 today, signaling weakened financials

Caris Life Sciences, Inc. has a net cash position, so leverage is healthy.

Caris Life Sciences, Inc.'s interest coverage ratio of 3.27 indicates that earnings with margin can cover interest payments on company debt

Caris Life Sciences, Inc.'s profit margin has increased (-115.54%) in the last year from -68.38% to 10.62%, signaling increasing performance

Caris Life Sciences, Inc.'s short-term assets of $997.80M exceed its short-term liabilities of $127.14M

Caris Life Sciences, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Caris Life Sciences, Inc.'s return on equity of 18.77%, is higher than 15.00%, indicating good performance

Caris Life Sciences, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Caris Life Sciences, Inc. has insufficient public price history to evaluate earnings stability.

Caris Life Sciences, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Caris Life Sciences, Inc. has a free cash flow yield of 1.01%, which is below the 2.00% threshold, indicating limited cash return relative to market value

Caris Life Sciences, Inc.'s yearly earnings has decreased 90.84% since last year from $-281.89M to $-537.96M, signaling decreasing performance

Caris Life Sciences, Inc.'s yearly revenue has increased 96.97% since last year from $412.26M to $812.03M, signaling increasing performance

ROIC 14.67% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Caris Life Sciences, Inc.'s 3-year revenue CAGR of 46.46% is positive, indicating growing revenue over the past 3 years

Caris Life Sciences, Inc. has insufficient public price history to evaluate revenue consistency.

Caris Life Sciences, Inc. has insufficient public price history to evaluate ROE consistency.

Caris Life Sciences, Inc. has insufficient data to evaluate this check.

Caris Life Sciences, Inc. has an earnings yield of 1.59%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

Caris Life Sciences, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Caris Life Sciences, Inc. has an EV/EBITDA ratio of 544.26x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

Caris Life Sciences, Inc. has insufficient data to evaluate this check.

Caris Life Sciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Caris Life Sciences, Inc. has a price-to-book ratio of 11.19x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Caris Life Sciences, Inc. has a price-to-sales ratio of 6.69x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue